Huda Suliman

Huda Suliman is President at Icaria Life Sciences. She spoke at the Ending Age-Related Diseases 2019, discussing her company’s role in the rejuvenation biotechnology ecosystem, including small molecule drug discovery and drug screening along with how her company deals with irreproducibility in the scientific literature. She explained how species differences are an issue, and she explained the differences between aging-focused and traditional medical research.
Icaria Life Sciences is the dedicated, preclinical contract research organization (CRO) for Ichor Therapeutics that broadly focuses on the study of aging and aging pathways. The company offers a number of services to support its clients and operates from its corporate offices in rural LaFayette, NY (south of Syracuse). The company is eager to engage collaborators and clients in industry and academia who share Ichor Therapeutics vision of delivering next generation therapies for the illness of aging. Their services include: GMP Compliance, Senolytic Research, Surgical Models, Xenograft Models, GLP Compliance, Rodent Husbandry, Stem Cell Research, Protein Engineering, Life Span Studies and Drug Discovery.